CYP Insider Trading

Insider Ownership Percentage: 12.20%
Insider Buying (Last 12 Months): A$12,426.88
Insider Selling (Last 12 Months): A$0.00

Cynata Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cynata Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cynata Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for CYP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!

Cynata Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2023Kilian KellyInsiderBuy94,143A$0.13A$12,426.88
11/20/2023Paul WottonInsiderIssued220,000A$0.12A$26,400.00
6/1/2023Darryl MaherInsiderIssued25,000A$0.14A$3,375.00
11/23/2022Janine RolfeInsiderIssued300,000A$0.35A$105,000.00
12/2/2021Stewart WasherInsiderBuy60,000A$0.51A$30,540.00
11/30/2020Paul WottonInsiderBuy300,000A$0.79A$237,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Cynata Therapeutics (ASX:CYP)

24.98% of Cynata Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Read More on Cynata Therapeutics

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


159,853 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Cynata Therapeutics?

Cynata Therapeutics' top insider investors include:
  1. Darryl Maher (Insider)
  2. Janine Rolfe (Insider)
  3. Kilian Kelly (Insider)
  4. Paul Wotton (Insider)
  5. Stewart Washer (Insider)
Learn More about top insider investors at Cynata Therapeutics.